Treatment of extranodal lymphomas

Best Practice and Research: Clinical Haematology

Volumn 15, Issue 3, 2002, Pages 533-547

  Zucca, Emanuele ^a   Conconi, Annarita ^b   Cavalli, Franco ^a  

^a OSPEDALE SAN GIOVANNI   (Switzerland)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Angiocentric T NKlymphoma; CNS; Extranodal; MALT lymphoma; Mycosis fungoides; Non Hodgkin's lymphoma; Skin; Stomach; Testis; Therapy

Indexed keywords

ANTHRACYCLINE; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BEXAROTENE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTARABINE; DENILEUKIN DIFTITOX; METHOTREXATE; METHOXSALEN; PROTON PUMP INHIBITOR; RITUXIMAB; STEROID; RETINOID X RECEPTOR;

CANCER INCIDENCE; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; GASTROINTESTINAL DISEASE; HISTOPATHOLOGY; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; MEDICAL DECISION MAKING; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NEUROTOXICITY; NONHODGKIN LYMPHOMA; NOSE DISEASE; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; PUVA; REVIEW; SKIN LYMPHOMA; TESTIS DISEASE; TISSUE SPECIFICITY; TREATMENT PLANNING; CENTRAL NERVOUS SYSTEM TUMOR; CLASSIFICATION; GASTROINTESTINAL TUMOR; PATHOLOGY; SKIN TUMOR; TREATMENT OUTCOME; B CELL LYMPHOMA; CLINICAL FEATURE; CLINICAL TRIAL; DIGESTIVE SYSTEM CANCER; HELICOBACTER PYLORI; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; SURVIVAL RATE; T CELL LYMPHOMA; TESTIS CANCER;

CENTRAL NERVOUS SYSTEM NEOPLASMS; GASTROINTESTINAL NEOPLASMS; HUMANS; LYMPHOMA, NON-HODGKIN; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 1842842444     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.2002.0218     Document Type: Article

References (93)

1. Zucca E, Roggero E, Bertoni F & Cavalli F. Primary extranodal non-Hodgkin's lymphomas. Part I: gastrointestinal, cutaneous and genitourinary lymphomas. Annals of Oncology 1997; 8: 727-737.
2. Zucca E, Roggero E, Bertoni F et al. Primary extranodal non-Hodgkin's lymphomas. Part 2: head and neck, central nervous system and other less common sites. Annals of Oncology 1999; 8: 1023-1033.
3. Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
4. Jaffe ES, Harris NL, Stein H & Vardiman JW (eds) Pathology & Genetics. Tumours of Hoematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumours. Lyon: IARC Press, 2001.
5. Groves FD, Linet MS, Travis LB & Devesa SS. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. Journal of National Cancer Institute 2000; 92: 1240-1251.
6. Zucca E, Bertoni F, Roggero E & Cavalli F. The gastric marginal zone B-cell lymphoma of MALT type. Blood 2000; 96: 410-419.
7. Wright DH, Jones DB, Clark H et al. Is adult-onset coeliac disease due to a low-grade lymphoma of intraepithelial T lymphocytes? Lancet 1991; 337: 1373-1374.
8. Cellier C, Delabesse E, Helmer C et al. Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. French Coeliac Disease Study Group. Lancet 2000; 356: 203-208.
9. Catassi C, Fabiani E, Corrao G et al. Risk of non-Hodgkin lymphoma in celiac disease. Journal of the American Medical Association 2002; 287: 1413-1419.
10. Daum S, Weiss D, Hummel M et al. Frequency of clonal intraepithelial T lymphocyte proliferations in enteropathy-type intestinal T cell lymphoma, coeliac disease, and refractory sprue. Gut 2001; 49: 804-812.
11. Rohatiner A. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract iymphoma. Annals of Oncology 1994; 5: 397-400.
12. De Jong D, Aleman BM, Taal BG & Boot H. Controversies and consensus in the diagnosis, work-up and treatment of gastric lymphoma: an international survey. Annals of Oncology 1999; 10: 275-280.
13. Wotherspoon AC, Doglioni C, Diss TC et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993; 342: 575-577.
14. Roggero E, Zucca E, Pinotti G et al. Eradication of Helicobacter pylori infection in primary low-grade gastric lymphoma of mucosa-associated lymphoid tissue. Annals of Internal Medicine 1995; 122: 767-769.
15. Montalban C, Manzanal A, Boixeda D et al. Helicobacter pylori eradication for the treatment of low-grade gastric MALT lymphoma: follow-up together with sequential molecular studies. Annals of Oncology 1997; 8 (supplement 2): 37-40.
16. Ruskone-Fourmestraux A, Lavergne A, Aegerter PH et al. Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment. Gut 2001; 48: 297-303.
17. Nakamura S, Matsumoto T, Suekane H et al. Predictive value of endoscopic ultrasonography for regression of gastric low grade and high grade MALT lymphomas after eradication of Helicobacter pylori. Gut 2001; 48: 454-460.
18. Steinbach G, Ford R, Glober G et al. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. Annals of Internal Medicine 1999; 131: 88-95.
19. Zucca E, Roggero E, Delchier JC et al. Interim evaluation of gastric MALT lymphoma response to antibiotics in the ongoing LY03 randomised cooperative trial of observation vs chlorambucil after anti-Helicobacter therapy. Proceedings of the American Society of Clinical Oncology 2000; 19: 5a.
20. Neubauer A, Thiede C, Morgner A et al. Cure of Helicobacter pylori infection and duration of remission of low- grade gastric mucosa-associated lymphoid tissue lymphoma. Journal of the National Cancer Institute 1997; 89: 1350-1355.
21. Savio A, Franzin G, Wotherspoon AC et al. Diagnosis and posttreatment follow-up of Helicobacter pyloripositive gastric lyrhphoma of mucosa-associated lymphoid tissue: histology, polymerase chain reaction, or both? Blood 1996; 87: 1255-1260.
22. Thiede C, Wundisch T, Alpen B et al. Long-term persistence of monoclonal B cells after cure of Helicobacter pylori infection and complete histologic remission in gastric mucosa-associated lymphoid tissue B-cell lymphoma. Journal of Clinical Oncology 2001; 19: 1600-1609.
23. Bertoni F, Concom A, Capella C et al. Molecular follow-up in gastric MALT lymphomas: early analysis from of the LY03 cooperative trial. Blood 2002; 99: 2541-2544.
24. Isaacson PG, Diss TC, Wotherspoon AC et al. Long-term follow-up of gastric MALT lymphoma treated by eradication of H. pylori with antibodies. Gastroenterology 1999; 117: 750-751.
25. Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A et al. Resistance of t(11;18) positive gastric mucosaassociated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet 2001; 357: 39-40.
26. Howden CW & Hunt RH. Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. American Journal of Gastroenterology 1998; 93: 2330-2338.
27. Hammel P, Haioun C, Chaumette MT et al. Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with promipent gastric expression. Journal of Clinical Oncology 1995; 13: 2524-2529.
28. Pinotti G, Zucca E, Roggero E et al. Clinical features, treatment and outcome in a series of 93 patients with low-grade gastric MALT lymphoma. Leukemia & Lymphoma 1997; 26: 527-537.
29. Tsang RW, Gospodarowicz MK, Pintilie M et al. Stage I and II MALT lymphoma: results of treatment with radiotherapy. International Journal of Radiation Oncology, Biology, Physics 2001; 50: 1258-1264.
30. Schechter NR, Portlock CS & Yahalom J. Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. Journal of Clinical Oncology 1998; 16: 1916-1921.
31. De Jong D, Boot H, van Heerde P et al. Histological grading in gastric lymphoma: pretreatment criteria and clinical relevance. Gastroenterology 1997; 112: 1466-1474.
32. Fung CY, Grossbard ML, Linggood RM et al. Mucosa-associated lymphoid tissue lymphoma of the stomach: long term outcome after local treatment. Cancer 1999; 85: 9-17.
33. Schechter NR & Yahalom J. Low-grade MALT lymphoma of the stomach: a review of treatment options. International Journal of Radiation Oncology, Biology, Physics 2000; 46: 1093-1103.
34. Cogliatti SB, Schmid U, Schumacher U et al. Primary B-cell gastric lymphoma: a clinicopathological study of 145 patients. Gastroenterology 1991; 101: 1159-1170.
35. Coiffier B & Salles G. Does surgery belong to medical history for gastric lymphoma? Annals of Oncology 1997; 8: 419-421.
36. Cortelazzo S, Rossi A, Roggero E et al. Stage-modified international prognostic index effectively predicts clinical outcome of localized primary gastric diffuse large B-cell lymphoma. International Extranodal Lymphoma Study Group. Annals of Oncology 1999; 10: 1433-1440.
37. Ibrahim EM, Ezzat AA, Raja MA et al. Primary gastric non-Hodgkin's lymphoma: clinical features, management, and prognosis of 185 patients with diffuse large B-cell lymphoma. Annals of Oncology 1999; 10: 1441-1449.
38. Gospodarowicz M. Individuality versus conformity. Is perfection necessary in staging and prognostic classifications of specific primary extranodal lymphomas? Annals of Oncology 1999; 10: 1405-1407.
39. Salles G, Herbrecht R, Tilly H et al. Aggressive primary gastrointestinal lymphomas: review of 91 patients treated with the LNH-83 regimen. A study of the GELA. American Journal of Medicine 1991; 90: 77-84.
40. Koch P, Del Valle F, Berdel WE et al. Primary gastrointestinal non-Hodgkin's lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma: results of the prospective German multicenter study GIT NHL 01/92. Journal of Clinical Oncology 2001; 19: 3874-3883.
41. Gobbi PG, Ghirardelli ML, Cavalli C et al. The role of surgery in the treatment of gastrointestinal lymphomas other than low-grade MALT lymphomas. Hoematologica 2000; 85: 372-380.
42. Seymour JF, Anderson RP & Bhathal PS. Regression of gastric lymphoma with therapy for Helicobacter pylori infection. Annals of Internal Medicine 1997; 127: 247.
43. Roggero E, Copie-Bergman C, Traullé C et al. Regression of high grade B-cell gastric lymphoma after eradication of Helicobacter pylori infection? Annals of Oncology 1999; 10 (supplement 3): 67.
44. Boot H, de Jong D, van Heerde P & Taal B. Role of Helicobacter pylori eradication in high-grade MALT lymphoma. Lancet 1995; 346: 448.
45. Montalban C, Santon A, Boixeda D & Bellas C. Regression of gastric high grade mucosa associated lymphoid tissue (MALT) lymphoma after Helicobacter pylori eradication. Gut 2001; 49: 584-587.
46. Morgner A, Miehlke S, Fischbach W et al. Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori infection. Journal of Clinical Oncology 2001; 19: 2041-2048.
47. Chen LT, Lin JT, Shyu RY et al. Prospective study of Helicobacter pylori eradication therapy in stage I(E) high-grade mucosa-associated lymphoid tissue lymphoma of the stomach. Journal of Clinical Oncology 2001; 19: 4245-4251.
48. Zinzani PL, Magagnoli M, Galieni P et al. Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients. Journal of Clinical Oncology 1999; 17: 1254-1258.
49. Thieblemont C, Berger F, Dumontet C et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients. Blood 2000; 95: 802-806.
50. Raderer M, Vorbeck F, Formanek M et al. Importance of extensive staging in patients with mucosa-associated lymphoid tissue (MALT)-type lymphoma. British Journal of Cancer 2000; 83: 454-457.
51. Cavalli F, Isaacson PG, Gascoyne RD & Zucca E. MALT Lymphomas. Hematology (Am Soc Hematol Educ Program) 2001; pp 241-258.
52. Conconi A, Thieblemont C, Martinelli G et al. Activity of rituximab in extranodal marginal-zone lymphomas (MALT-type). Blood 2001; 98: 807a(3354).
53. Willernze R, Kerl H, Sterry W et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997; 90: 354-371.
54. Jaffe ES, Sander CA & Flaig Mj. Cutaneous lymphomas: a proposal for a unified approach to classification using the REAL/WHO Classification. Annals of Oncology 2000; 11 (supplement 1): 17-21.
55. Siegel RS, Pandolfino T, Guitart J et al. Primary cutaneous T-cell lymphoma: review and current concepts. Journal of Clinical Oncology 2000; 18: 2908-2925.
56. Diamandidou E, Cohen PR & Kurzrock R. Mycosis fungoides and Sezary syndrome. Blood 1996; 88: 2385-2409.
57. Vergier B, de Muret A, Beylot-Barry M et al. Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. Blood 2000; 95: 2212-2218.
58. Duvic M. Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms. Clinical Lymphoma 2000; 1 (supplement 1): S51-S55.
59. Duvic M, Hymes K, Heald P et al. Bexarotene Worldwide Study Group. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. Journal of Clinical Oncology 2001; 19: 2456-2471.
60. Olsen E, Duvic M, Frankel A et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology 2001; 19: 376-388.
61. Pandolfino TL, Siegel IRS, Kuzel TM et al. Primary cutaneous B-cell lymphoma: review and current concepts. Journal of Clinical Oncology 2000; 18: 2152-2168.
62. Grange F, Bekkenk MW, Wechsler J et al. Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study. Journal of Clinical Oncology 2001; 19: 3602-3610.
63. Roggero E, Zucca E, Mainetti C et al. Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin. Human Pathology 2000; 31: 263-268.
64. Sarris AH, Braunschweig I, Medeiros LJ et al. Primary cutaneous non-Hodgkin's lymphoma of Ann Arbor stage 1: preferential cutaneous relapses but high cure rate with doxorubicin-based therapy. Journal of Clinical Oncology 2001; 19: 398--405.
65. Paul T, Radny P, Krober SM et al. Intralesional rituximab for cutaneous B-cell lymphoma. British Journal of Dermatology 2001; 144: 1239-1243.
66. Heinzerling LM, Urbanek M, Funk JO et al. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. Cancer 2000; 89: 1835-1844.
67. Fine HA & Loeffler JS. Primary central nervous system lymphoma. In Canellos GP, Lister TA & Sklar JL (eds) The Lymphomas, pp 481-494. Philadelphia: WB Saunders, 1998.
68. Ferreri AJM, Blay J-Y, Pasini F et al. Predictors of survival in primary central nervous system lymphoma (PCNSL): analysis of an international multicentre series of 378 immunocompetent patients. Blood 2000; 96: (abstract 1438).
69. Blay J-Y, Conroy T, Chevreau C et al. High dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. Journal of Clinical Oncology 1998; 16: 864-871.
70. Abrey LE, DeAngelis LM & Yahalom J. Long-term survival in primary central nervous system lymphoma. Journal of Clinical Oncology 1998; 16. 859-863.
71. O'Brien P, Roos D, Pratt G et al. Phase II multicentric study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. Journal of Clinical Oncology 2000; 18: 519-526.
72. Reni M, Ferreri AJ, Guha-Thakurta N et al. Clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary central nervous system lymphomas treated with upfront high-dose methotrexate. Internationel Journal of Radiation Oncology, Biology, Physics 2001; 51: 419-425.
73. Ferreri AJM, Reni M, Pasini F et al. A multicenter study of treatment of primary CNS lymphoma. Neurology (in press).
74. Soussain C, Suzan F, Hoang-Xuan K et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. Journal of Clinical Oncology 2001; 19: 742-749.
75. Abrey LE, Moskowitz CH, Mason WP et al. A phase II study of intensive methotrexate and cytarabine followed by high dose BEAM chemotherapy with autologous stem cell transplantation (ASCT) in patients with newly diagnosed primary central nervous system lymphoma (PCNLS). Proceedings of the American Society of Clinical Oncology 2001; 53a: (abstract 207).
76. Freilich RJ, Delattre JY, Monjour A et al. Chemotherapy without radiation therapy as initial treatment for primary central nervous system lymphoma in older patients. Neurology 1996; 46: 435-439.
77. Abrey LE, Yahalom J & DeAngelis LM. Treatment for primary CNS lymphoma: the next step. Journal of Clinical Oncology 2000; 18: 3144-3150.
78. Shultz C, Scott C, Sherman W et al. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of Radiation Therapy Oncology Group Protocol 88-06. Journal of Clinical Oncology 1996; 14: 556-564.
79. Cesarman E, Chang Y, Moore PS et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. New England Journal of Medicine 1995; 332: 1186-1191.
80. Nador RG, Cesarman E, Chadburn A et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood 1996; 88: 645-656.
81. Gaidano G & Carbone A. Primary effusion lymphoma: a liquid-phase lymphoma of fluid-filled body cavities. Advances in Cancer Research 2001; 80: 115-146.
82. Chan JKC, Jaffe ES & Ralfkiaer E. Extranodal NK/T-cell lymphoma, nasal type. In Jaffe ES, Harris NL, Stein H & Vardiman JW (eds) Pathology & Genetics. Tumours of Hoematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumours, pp 204-207. Lyon: IARC Press, 2001.
83. Jaffe ES, Chan JKC, Su LJ et al. Report of the workshop on nasal and related extranodal angiocentric T/Natural Killer cell lymphomas. Definitions, differential diagnosis, and epidemiology. American Journal of Surgical Pathology 1996; 20: 103-111.
84. Mraz-Gernhard S, Natkunam Y, Hoppe RT et al. Natural killer/natural killer-like T-cell lymphoma, CD56+, presenting in the skin: an increasingly recognized entity with an aggressive course. Journal of Clinical Oncology 2001; 19: 2179-2188.
85. Kim GE, Cho JH, Yang WI et al. Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. Journal of Clinical Oncology 2000; 18: 54-63.
86. Kim WS, Song SY, Ahn YC et al. CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma? Annals of Oncology 2001; 12: 49-352.
87. Fonseca R, Habermann TM, Colgan JP et al. Testicular lymphoma i associated with a high incidence of extranodal recurrence. Cancer 2000; 88: 154-161.
88. Tondini C, Ferreri AJM, Siracusano L et al. Diffuse large lymphoma of the testis. Journal of Clinical Oncology 1999; 17: 2854-2858.
89. Seymour JF, Solomon B, Wolf MM et al. Primary large-cell non-Hodgkin's lymphoma of the testis: a retrospective analysis of patterns of failure and prognostic factors. Clinical Lymphoma 2001; 2: 109-115.
90. Visco C, Medeiros LJ, Mesina OM et al. Non-Hodgkin's lymphoma affecting the testis: is it curable with doxorubicin-based therapy? Clinical Lymphoma 2001; 2: 40-46.
91. Zouhair A, Weber D, Belkacemi Y et al. Outcome and patterns of failure in testicular lymphoma: a multicenter Rare Cancer Network study. International Journal of Radiation Oncology, Biology, Physics 2002; 52: 652-656.
92. Connors JM, Klimo P, Voss N et al. Testicular lymphoma: Improved outcome with early brief chemotherapy. Journal of Clinical Oncology 1988; 6: 776-781.
93. Gospodarowicz M K, Zucca E. Primary testis lymphoma: presentation, treatment, pattern of failure, and outcomes. In Perry MC (ed) American Society of Clinical Oncology Educational Book, pp 281-285. Alexandria VA, USA: ASCO, Spring 2001.